International Myeloma Society 15 th International Myeloma Workshop September 22, 2015

1. International Myeloma Society 15th International Myeloma Workshop September 22, 2015 Rome, Italy

2. The International Myeloma Society Established as non-profit corporation in 2008 Aims to promote research, education, clinical studies, workshops, conferences, and symposia on all aspects of multiple myeloma and related disorders worldwide.

3. Eligibility for Membership Any individual who has demonstrated a vital and continuing interest in the field of myeloma is eligible for membership. Scientists, clinicians, industry representatives, members of advocacy groups, and patients and/or their families are welcome to join.

4. The International Myeloma Society Membership Benefits: Sponsor abstract at IMW Educational book from IMW Discounted registration at IMW and IMS sponsored events Free online subscription to Clinical Lymphoma and Myeloma Eligible to be a candidate for Board of Directors, Awards, Travel Grants, Host the IMW Nomination and election process

5. The International Myeloma Society Our website www.myelomasociety.org Provides information about IMS, its officers and programs, as well as an easy application for membership. Describes our mission and ultimately will evolve to an online up-to-date data base for ongoing basic and clinical research studies in myeloma, as well as International Myeloma Society member demographics. Will have links to programs for International Myeloma Workshops, as well as other basic and clinical myeloma meetings.

6. 2015 Officers IMS President Kenneth C. Anderson, MDDana Farber Cancer Institute Boston, MA president@myelomasociety.org Vice-President Jesús San Miguel , MDHospital Clinico Universitario Salamanca, Spain vicepresident@myelomasociety.org Secretary Joan Bláde, MDHospital Clinic, HematologyBarcelona, Spainsecretary@myelomasociety.org Treasurer Angela Dispenzieri, MD Mayo Clinic, Hematology Rochester, MNtreasurer@myelomasociety.org

7. Board of Directors IMS *completing terms Michel Attal , MD* Hospital Purpan Toulouse, France Hervé Avet-Loiseau, MD Universitaire De Nantes Nantes, France . Meletios-Athanassios Dimopoulos, MD University of Athens Athens, Greece Sagar Lonial, MD* Emory UniversityAtlanta, GA Andrew Spencer, MD* Monash UniveristyVictoria, Australia Nikhil C. Munshi, MD*Dana Farber Cancer InstituteBoston, MA Angelo Maiolino, MD Universidade Federal do Rio de Janeiro Rio de Janeiro, Brazil Gareth Morgan, MD University of Arkansas Little Rock, AR Hirokazu Murakami, MD Gunma University Graduate School of Health Sciences Maebashi, Japan Robert A. Kyle, MD Immediate Past PresidentMayo ClinicRochester, MN

8. 2015 Officers IMS President Jesús San Miguel , MDHospital Clinico Universitario Salamanca, Spain president@myelomasociety.org Vice-President Nikhil C. Munshi, MD*Dana Farber Cancer InstituteBoston, MA vicepresident@myelomasociety.org Secretary Sagar Lonial, MD Emory UniversityAtlanta, GA secretary@myelomasociety.org Treasurer Angela Dispenzieri, MD Mayo Clinic, Hematology Rochester, MNtreasurer@myelomasociety.org

9. Hervé Avet-Loiseau, MD Universitaire De Nantes Nantes, France . Meletios-Athanassios Dimopoulos, MD University of Athens Athens, Greece Maria V Mateos, MD University of Salamanca Salamanca, Spain Shaji Kumar, MD Mayo Clinic Rochester, MN Donna Reece, MD Princess Margaret Hospital Toronto, Canada Board of Directors IMS 2015-2016 Douglas Joshua, MD Royal Prince Alfred Hospital Sydney, Australia Angelo Maiolino, MD Universidade Federal do Rio de Janeiro Rio de Janeiro, Brazil Gareth Morgan, MD University of Arkansas Little Rock, AR Hirokazu Murakami, MD Gunma University Graduate School of Health Sciences Maebashi, Japan Kenneth C. Anderson, MD Immediate Past PresidentDana-Farber Cancer Institute Boston, MA

10. IMS and the International Myeloma Workshop Establishes an equitable process for solicitation of proposals and the selection of sites for our biannual International Myeloma Workshops. Assures that venues are chosen for future workshops which have appropriate meeting space, accommodations, and transportation, with a sponsoring institution and organizing committee.

11. IMS and the International Myeloma Workshop Provides assistance in defining the breadth and quality of content represented at the International Myeloma Workshops to include cutting-edge scientific and clinical advances, as well as all aspects of current diagnosis, prognosis, and treatment of myeloma.

12. 16th International Myeloma Workshop March 1-4, 2017 New Delhi, India Co-Chairs: NoopurRaje, M.D., Shaji Kumar, M.D. SagarLonial, M.D.

13. Applying to Host 2019 IMW Deadline for proposals is October 1, 2015 Criteria for hosting IMW meeting includes: Meeting Space - One should plan for up to 3,000 attendees.   Accommodations - There should be approximately 2,500 sleeping rooms within easy commuting distance.   Transportation - The host city should be within one hour from a major International airport.

14. Applying to Host 2019 IMW Please state the approximate proposed dates in 2019, sponsoring institution and organizing committee Deadline for application is: October 1, 2015. Applications will be discussed at ASH IMS Board Meeting, where a decision will be made. Announcement of venue will be made in January 2016. Please send application to IMS president for review to kenneth_anderson@dfci.harvard.edu and copy Lisa Sikkink

15. Waldenstrom Award Honors the seminal contributions of Jan Waldenstrom to plasma cell dyscrasias Awarded to an individual in recognition of outstanding contributions to the field of multiple myeloma

16. Waldenstrom Award The Waldenström Committee: Composed of 10 recognized persons in the myeloma field and also representing different geographical areas. The current composition is Joan Bladé, Chair, Robert Kyle, Hervé Avet-Loisseau, Brian Durie, Angelo Maiolino, Giampaolo Merlini, Linda Pilarski, Andrew Spencer, Donna Reece, and Kazuyuki Shimizu. The WA Committee elaborated the basis for a structured document of Merits (CV) to be asked to the potential nominees.

17. Waldenstrom Award Nominations: Each member of the IMS Board and each member of the Waldenström Award Committee selected two candidates, and the four with the most votes were nominated for the Waldenström Award. All of the four nominees were then asked to complete the Documents and Merits developed by the Waldenström Award Committee, which is circulated among the electors.

18. Waldenstrom Award Final Election: The members of the IMS Board, members of the WA Committee, previous Waldenström’s awardees, prior organizers of the International Myeloma Workshops each vote for only one nominee, and the one who obtains the most votes becomes the awardee.

19. Bart Barlogie Young Investigator Award Established by IMS BOD to honor the seminal contributions of Dr. Bart Barlogie to myeloma treatment Awarded to an individual (< 40 years old) to both recognize and stimulate excellence in myeloma research $25,000 USD to support the Award winner’s research.

20. Bart Barlogie Young Investigator Award Personal data: Date of birth, institution, your current position and director of your research. Field of myeloma research: brief description of your clinical/lab/research activities. Research: original papers, reviews, book chapters, any consensus statements and abstracts at major meetings. Funded Research. Honours and Prizes. Teaching and Training activities. Five top publications in which you are first or senior author. Three top clinical and/or technology achievements/innovations.

21. Bart Barlogie Young Investigator Award Application Evaluation Each eligible application will be reviewed by the current members of the International Myeloma Society (IMS) Board and members of the Waldenström`s Award Committee (WA) who hold current membership in the IMS. The members of the IMS Board and the WA Committee will be the electors by voting for only one applicant. Any member, either IMS or WA, who are directly linked to the applicant will have access to the applications but will not be involved in the voting process.

22. Travel Grants Age 35 years or younger Member of IMS Registered for IMW Have an abstract selected for oral or poster presentation at IMW $2,000 USD to support travel to IMW

23. Clinical Lymphoma, Myeloma, and Leukemia ISSN: 2152-2650 Current Vol: 15 Frequency: Monthly Senior Editor: Sundar Jagannath, MD Editor, Myeloma: Sagar Lonial, MD Society: International Myeloma Society, Society of Hematologic Oncology Impact Factor: 2.02 (Increased from 1.6) Print Circulation: 10,000+ Rejection Rate: 70% Article downloads per month: 5,222 Will consider for publication: original research (including clinical trials), meta-analyses, reviews, current trial reports, case studies Open access publication opportunities: $1700.00 sponsorship fee Article submission: http://ees.elsevier.com/clml

24. International Myeloma Society & Elsevier • Elsevier provides free online access to CLML to IMS members (optional discounted print subscription rate of USD $95 (US) or USD $145 (International)) • Elsevier will publish “IMS Update” (limit 8,000 words print, unlimited online), which is provided by the IMS • Elsevier provides IMS all publication schedules upon request • Elsevier will publish one color advertising page in each issue of the Journal (non‐covers). Ad provided by IMS • Clinical Lymphoma, Myeloma & Leukemia carries "Official Journal of the International Myeloma Society” on its cover and all branded marketing communications • Elsevier offers revenue‐sharing supplement opportunities (print/online). IMS provides expertise on content

25. The International Myeloma Society Promotes continued innovative collaborative research in myeloma Assures that resultant scientific advances are translated to improved diagnosis, prognosis, and treatment of myeloma for patients worldwide. Fosters training of the next generation of leaders in myeloma basic and translational research.

26. The International Myeloma Society Achieving these goals will: assure that we can together capitalize on current opportunities to genetically and molecularly define disease pathogenesis; rapidly derive, validate, and provide access to effective novel therapies for all patients; and ultimately develop curative myeloma therapies. IF YOU ARE NOT A MEMBER, PLEASE JOIN TODAY